Literature DB >> 1977249

Increased levels of immunoreactive leukotriene B4 in blister fluids of bullous pemphigoid patients and effects of a selective 5-lipoxygenase inhibitor on experimental skin lesions.

S Kawana1, A Ueno, S Nishiyama.   

Abstract

The immunoreactive leukotriene B4 (i-LTB4) and i-LTC4 content in the blister fluids of patients with bullous pemphigoid (BP) was determined by radioimmunoassay. Their amounts significantly exceeded those noted in superficial dermal burn patients and those in the fluids of suction blisters produced on normal human skin. When either BP blister fluids or BP-IgG from the patient sera were injected into guinea pig skin, neutrophil and eosinophil infiltrates were produced in the dermis. In addition, the dermis was noted to undergo marked edematous change. A single oral administration of a selective inhibitor of 5-lipoxygenase 1 hr before the intracutaneous injection of BP-IgG was found to significantly inhibit cell infiltrates. Furthermore, the inhibitor partly suppressed dermal epidermal separation. On the basis of these results. LTB4 and LTC4 appear to be generated in the skin lesions of BP, the former attracting granulocytes to the dermis and the latter, causing exudation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1977249     DOI: 102340/0001555570281285

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  8 in total

1.  Increased immunoreactive interleukin-5 levels in blister fluids of bullous pemphigoid.

Authors:  H Endo; I Iwamoto; M Fujita; S Okamoto; S Yoshida
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

2.  Dual inhibition of complement factor 5 and leukotriene B4 synergistically suppresses murine pemphigoid disease.

Authors:  Tanya Sezin; Sripriya Murthy; Claudia Attah; Malte Seutter; Maike M Holtsche; Christoph M Hammers; Enno Schmidt; Fibi Meshrkey; Sadegh Mousavi; Detlef Zillikens; Miles A Nunn; Christian D Sadik
Journal:  JCI Insight       Date:  2019-08-08

Review 3.  A Review of the Immunologic Pathways Involved in Bullous Pemphigoid and Novel Therapeutic Targets.

Authors:  Mohsen Afarideh; Robert Borucki; Victoria P Werth
Journal:  J Clin Med       Date:  2022-05-18       Impact factor: 4.964

4.  Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid.

Authors:  R Chen; G Ning; M L Zhao; M G Fleming; L A Diaz; Z Werb; Z Liu
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

5.  Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model.

Authors:  Zhi Liu; Wen Sui; Minglang Zhao; Zhuowei Li; Ning Li; Randy Thresher; George J Giudice; Janet A Fairley; Cassian Sitaru; Detlef Zillikens; Gang Ning; M Peter Marinkovich; Luis A Diaz
Journal:  J Autoimmun       Date:  2008-10-14       Impact factor: 7.094

Review 6.  The pathophysiology of bullous pemphigoid.

Authors:  Michael Kasperkiewicz; Detlef Zillikens
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 8.667

Review 7.  Experimental models for the autoimmune and inflammatory blistering disease, Bullous pemphigoid.

Authors:  Lisa Leighty; Ning Li; Luis A Diaz; Zhi Liu
Journal:  Arch Dermatol Res       Date:  2007-09-19       Impact factor: 3.017

Review 8.  The Autoimmune Skin Disease Bullous Pemphigoid: The Role of Mast Cells in Autoantibody-Induced Tissue Injury.

Authors:  Hui Fang; Yang Zhang; Ning Li; Gang Wang; Zhi Liu
Journal:  Front Immunol       Date:  2018-03-01       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.